1
|
Bertocchio JP, Grosset N, Groussin L, Kamenický P, Larceneux F, Lienhardt-Roussie A, Linglart A, Maruani G, Mirallie E, Pattou F, Seervai RNH, Sido C, Silve C, Vilfaillot A, Tabarin A, Vantyghem MC, Houillier P. Practice patterns for chronic hypoparathyroidism: data from patients and physicians in France. Endocr Connect 2022; 11:EC-21-0350.R2. [PMID: 34939939 PMCID: PMC8859964 DOI: 10.1530/ec-21-0350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Accepted: 12/23/2021] [Indexed: 11/28/2022]
Abstract
CONTEXT Recent guidelines have provided recommendations for the care of patients with chronic hypoparathyroidism. Very little is known about actual physicians' practices or their adherence to such guidelines. OBJECTIVE To describe the physicians' practice patterns and their compliance with international guidelines. DESIGN The cohort studies included were Épi-Hypo (118 physicians and 107 patients, from September 2016 to December 2019) and ePatients (110 patients, November 2019). METHODS Internet-based cohorts involving all settings at a nationwide level (France). Participants were (i) physicians treating patients with chronic hypoparathyroidism and patients with chronic hypoparathyroidism either participating in the (ii) Épi-Hypo study (Épi-Hypo 2019 patients), or (iii) Hypoparathyroidism France, the national representative association (ePatients). RESULTS The physicians' specialties were mainly endocrinology (61%), nephrology (28%), family medicine (2.5%), pediatrics (2.5%), rheumatology (2%), or miscellaneous (4%) and 45% were practicing in public universities. The median number of pharmaceutical drug classes prescribed was three per patient. The combination of active vitamin D and calcium salt was given to 59 and 58% of ePatients and Épi-Hypo 2019 patients, respectively. Eighty-five percent of ePatients and 87% of physicians reported monitoring plasma calcium concentrations at a steady state at least twice a year. In 32 and 26% of cases, respectively, ePatients and physicians reported being fully in accordance with international guidelines that recommend targeting symptoms, plasma calcium and phosphate values, and urine calcium excretion. CONCLUSIONS The care of patients with chronic hypoparathyroidism involves physicians with very different practices, so guidelines should include and target other specialists as well as endocrinologists. Full adherence to the guidelines is low in France.
Collapse
Affiliation(s)
- Jean-Philippe Bertocchio
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Physiologie, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, INSERM, UMRS1138, Paris, France
- Correspondence should be addressed to J-P Bertocchio or P Houillier: or
| | | | - Lionel Groussin
- Department of Endocrinology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Université de Paris, Paris, France
| | - Peter Kamenický
- Université Paris-Saclay, Inserm U1185, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, Le Kremlin-Bicêtre, France
| | - Fabrice Larceneux
- Université Paris-Dauphine, PSL Research University, CNRS, UMR 7088, DRM [Ermes], Paris, France
| | | | - Agnès Linglart
- Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
- Université Paris-Saclay, Inserm U1185, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Service d’Endocrinologie et Diabète de l’Enfant, Centre de Référence des Maladies Rares du Calcium et du Phosphore et Filière de Santé Maladies Rares OSCAR, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre, France
| | - Gérard Maruani
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Physiologie, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
- Assistance Publique-Hôpitaux de Paris, Institut Necker-Enfants Malades, INSERM U1151 – CNRS UMR 8253, Paris, France
| | - Eric Mirallie
- Chirurgie Cancérologique, Digestive et Endocrine, Institut des Maladies de l’Appareil Digestif, Hôtel Dieu, CHU Nantes, France
- Association Francophone de Chirurgie Endocrinienne (AFCE), France
| | - François Pattou
- Université de Lille, CHU Lille, Institut Pasteur Lille, Inserm U1190, Lille, France
| | - Riyad N H Seervai
- Molecular & Cellular Biology Graduate Program, Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, USA
| | | | - Caroline Silve
- Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Biochimie et Génétique Moléculaires, Paris, France
- INSERM, U1169, Université Paris Sud, Hôpital Bicêtre, Le Kremlin Bicêtre, France
| | - Aurélie Vilfaillot
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Unité de Recherche Clinique, Paris, France
- INSERM, U1418, CIC-EC, Hôpital Européen Georges Pompidou, Paris, France
| | - Antoine Tabarin
- Service Endocrinologie Diabète et Nutrition, CHU de Bordeaux, Université de Bordeaux, Pessac, France
| | - Marie-Christine Vantyghem
- CHU Lille, Department of Endocrinology, Diabetology and Metabolism, Inserm U1190, EGID, Lille, France
| | - Pascal Houillier
- Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Physiologie, Paris, France
- Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, INSERM, UMRS1138, Paris, France
- CNRS, ERL8228, Paris, France
- Correspondence should be addressed to J-P Bertocchio or P Houillier: or
| | | |
Collapse
|
2
|
Flot C, Porquet-Bordes V, Bacchetta J, Rothenbuhler A, Lienhardt-Roussie A, Giabicani E, Gueorguieva I, Storey C, Linglart A, Salles JP, Edouard T. Demographic Characteristics, Risk Factors, and Presenting Features of Children with Symptomatic Nutritional Rickets: A French Series. Horm Res Paediatr 2021; 93:304-312. [PMID: 33120384 DOI: 10.1159/000511419] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 09/03/2020] [Indexed: 12/19/2022] Open
Abstract
AIM To describe the demographic characteristics, risk factors, and presenting features of children with symptomatic nutritional rickets in France. METHODS This is a retrospective study of 38 children diagnosed with nutritional rickets from 1998 to 2019. RESULTS We observed a higher frequency of rickets in males (74 vs. 26%), in young children (median age at diagnosis: 23 months; 82% were younger than 5 years), and in children with a non-Caucasian ethnic background (89%). Most children were exclusively breastfed (78%) without adequate vitamin D supplementation (89%). The most common presentations were bowed legs (63%), hypocalcemic seizures (21%), and growth retardation (11%). Approximately half (62%) of the children were hypocalcemic. The children presenting with hypocalcemic seizures were significantly younger (0.8 vs. 2.2 years; p = 0.041) and had lower total serum calcium levels (1.44 vs. 2.17 mmol/L; p < 0.0001), higher phosphatemia (1.43 vs. 1.23 mmol/L; p = 0.020), and lower 25-hydroxy vitamin D levels (3 vs. 7 ng/mL; p = 0.020) but similar parathyroid hormone levels (357 vs. 289 ng/mL; p = 0.940) compared to rickets cases who did not experience hypocalcemic seizures. A dilated cardiomyopathy was detected in 14% of the children who had undergone echocardiography. CONCLUSION Nutritional rickets remains endemic in the pediatric population and its most severe forms can have life-threatening sequelae. Health practitioners need to be cognizant of these facts to raise awareness and screen high-risk populations.
Collapse
Affiliation(s)
- Claire Flot
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Unité d'Endocrinologie, Maladies Osseuses et Génétique, Hôpital des Enfants, CHU de Toulouse, ERN BOND, INSERM UMR 1043/CNRS 5828, Université Paul Sabatier, Toulouse, France
| | - Valérie Porquet-Bordes
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Unité d'Endocrinologie, Maladies Osseuses et Génétique, Hôpital des Enfants, CHU de Toulouse, ERN BOND, INSERM UMR 1043/CNRS 5828, Université Paul Sabatier, Toulouse, France
| | - Justine Bacchetta
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Hôpital Femme Mère Enfant, INSERM UMR 1033, Bron, France
| | - Anya Rothenbuhler
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Endocrinology and Diabetology for Children, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre, France
| | - Anne Lienhardt-Roussie
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Service de Pédiatrie, CHU de Limoges, Limoges, France
| | - Eloise Giabicani
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Sorbonne Université, INSERM, Centre de Recherche Saint Antoine, APHP, Explorations Fonctionnelles Endocriniennes Hôpital Armand Trousseau, Paris, France
| | - Iva Gueorguieva
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Service d'Endocrinologie Pédiatrique Hôpital Jeanne de Flandres, CHR Lille, Lille, France
| | - Caroline Storey
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Département d'Endocrinologie et Diabétologie Pédiatrique, Hôpital Universitaire Robert-Debré, Paris, France
| | - Agnès Linglart
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Endocrinology and Diabetology for Children, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre, France
| | - Jean-Pierre Salles
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France.,Unité d'Endocrinologie, Maladies Osseuses et Génétique, Hôpital des Enfants, CHU de Toulouse, ERN BOND, INSERM UMR 1043/CNRS 5828, Université Paul Sabatier, Toulouse, France
| | - Thomas Edouard
- Reference and Competence Centers for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Diseases, Paris, France, .,Unité d'Endocrinologie, Maladies Osseuses et Génétique, Hôpital des Enfants, CHU de Toulouse, ERN BOND, INSERM UMR 1043/CNRS 5828, Université Paul Sabatier, Toulouse, France,
| |
Collapse
|
3
|
Bertocchio JP, Grosset N, Groussin L, Kamenicky P, Larceneux F, Lienhardt-Roussie A, Linglart A, Maruani G, Mirallie E, Pattou F. Épi-Hypo : état des lieux du suivi des recommandations pour la prise en charge de l’hypoparathyroïdie chronique en France. Nephrol Ther 2021. [DOI: 10.1016/j.nephro.2021.07.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
El Allali Y, Hermetet C, Bacchetta J, Amouroux C, Rothenbuhler A, Porquet-Bordes V, Champigny MA, Baron S, Barat P, Bony-Trifunovic H, Bourdet K, Busiah K, Cartigny-Maciejewski M, Compain F, Coutant R, Amsellem-Jager J, De Kerdanet M, Magontier N, Mignot B, Richard O, Rossignol S, Soskin S, Berot A, Naud-Saudreau C, Salles JP, Linglart A, Edouard T, Lienhardt-Roussie A. Presenting features and molecular genetics of primary hyperparathyroidism in the paediatric population. Eur J Endocrinol 2021; 184:347-355. [PMID: 33361469 DOI: 10.1530/eje-20-1119] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Accepted: 11/28/2020] [Indexed: 11/08/2022]
Abstract
AIM To describe the presenting features and molecular genetics of primary hyperparathyroidism (PHPT) in the paediatric population. METHODS Retrospective study of 63 children diagnosed with primary PHPT from 1998 to 2018. RESULTS Compared to older children, infants were often asymptomatic (54% vs 15%, P = 0.002) with a milder form of PHPT. When symptomatic, children and adolescents mostly presented with non-specific complaints such as asthenia, depression, weight loss, vomiting or abdominal pain. A genetic cause of PHPT was identified in about half of this cohort (52%). The infancy period was almost exclusively associated with mutation in genes involved in the calcium-sensing receptor (CaSR) signalling pathway (i.e. CaSR and AP2S1 genes, 'CaSR group'; 94% of infants with mutations) whereas childhood and adolescence were associated with mutation in genes involved in parathyroid cell proliferation (i.e. MEN1, CDC73, CDKN1B and RET genes, 'cell proliferation group'; 69% of children and adolescents with mutations). Although serum calcium levels did not differ between the two groups (P = 0.785), serum PTH levels and the urinary calcium/creatinine ratio were significantly higher in 'cell proliferation group' patients compared to those in the 'CaSR group' (P = 0.001 and 0.028, respectively). CONCLUSION Although far less common than in adults, PHPT can develop in children and is associated with significant morbidity. Consequently, this diagnosis should be considered in children with non-specific complaints and lead to monitoring of mineral homeostasis parameters. A genetic cause of PHPT can be identified in about half of these patients.
Collapse
Affiliation(s)
| | - Coralie Hermetet
- Epidemiology and Public Health Unit, Tours University Hospital, Tours, Centre, France
| | - Justine Bacchetta
- Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Centre de Référence des Maladies Rares du Calcium et du Phosphore, Hôpital Femme Mère Enfant, INSERM UMR 1033, Bron, France
| | - Cyril Amouroux
- Paediatric Unit, Montpellier University Hospital, Montpellier, Languedoc-Roussillon, France
| | - Anya Rothenbuhler
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre Paris Saclay, Endocrinology and Diabetology for Children, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Le Kremlin-Bicêtre, Toulouse, France
| | - Valérie Porquet-Bordes
- Endocrine, Bone Diseases, and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Children's Hospital, Toulouse University Hospital, INSERM UMR 1043/CNRS 5828, Paul Sabatier University, Toulouse, France
| | | | - Sabine Baron
- Paediatric Unit, Nantes University Hospital, Nantes, Pays de la Loire, France
| | - Pascal Barat
- Paediatric Unit, Bordeaux University Hospital, Bordeaux, Aquitaine, France
| | | | - Karine Bourdet
- Paediatric Unit, Brest University Hospital, Brest, Bretagne, France
| | - Kanetee Busiah
- Endocrinology and Diabetology for Children, Necker University Hospital, AP-HP, Paris, Île-de-France, France
| | | | | | - Régis Coutant
- Paediatric Endocrinology Department, Angers University Hospital, Angers, Pays de la Loire, France
| | - Jessica Amsellem-Jager
- Paediatric Endocrinology Department, Angers University Hospital, Angers, Pays de la Loire, France
| | - Marc De Kerdanet
- Paediatric Unit, Rennes University Hospital, Rennes, Bretagne, France
| | | | - Brigitte Mignot
- Paediatric Unit, Besançon University Hospital, Besançon, France
| | - Odile Richard
- Paediatric Unit, Saint-Etienne University Hospital, Saint-Etienne, Rhône-Alpes, France
| | - Sylvie Rossignol
- Paediatric Unit, Strasbourg University Hospital, Strasbourg, Alsace, France
| | - Sylvie Soskin
- Paediatric Unit, Strasbourg University Hospital, Strasbourg, Alsace, France
| | - Aurélie Berot
- Paediatric Unit, Reims University Hospital, Reims, Champagne-Ardenne, France
| | | | - Jean-Pierre Salles
- Endocrine, Bone Diseases, and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Children's Hospital, Toulouse University Hospital, INSERM UMR 1043/CNRS 5828, Paul Sabatier University, Toulouse, France
| | - Agnès Linglart
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre Paris Saclay, Endocrinology and Diabetology for Children, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Le Kremlin-Bicêtre, Toulouse, France
| | - Thomas Edouard
- Endocrine, Bone Diseases, and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Children's Hospital, Toulouse University Hospital, INSERM UMR 1043/CNRS 5828, Paul Sabatier University, Toulouse, France
| | | |
Collapse
|
5
|
Guibert H, Lienhardt-Roussie A, Fayemendy P, Morin B, Voisin A, Thibault H, Desport J, Jésus P. Prise en charge et dépistage de l’obésité infantile : pratiques et attentes des médecins généralistes et des pédiatres libéraux du Limousin. NUTR CLIN METAB 2019. [DOI: 10.1016/j.nupar.2019.01.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
6
|
Goursaud C, Mallet D, Janin A, Menassa R, Tardy-Guidollet V, Russo G, Lienhardt-Roussie A, Lecointre C, Plotton I, Morel Y, Roucher-Boulez F. Aberrant Splicing Is the Pathogenicity Mechanism of the p.Glu314Lys Variant in CYP11A1 Gene. Front Endocrinol (Lausanne) 2018; 9:491. [PMID: 30233493 PMCID: PMC6134065 DOI: 10.3389/fendo.2018.00491] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 08/06/2018] [Indexed: 12/30/2022] Open
Abstract
Context: The cholesterol side chain cleavage enzyme (CYP11A1) catalyzes the conversion of cholesterol to pregnenolone, the first rate-limiting step of steroidogenesis. CYP11A1 mutations are associated with primary adrenal insufficiency (PAI) as well as disorders of sex development (DSD) in 46,XY patients. Objective: To define the pathogenicity mechanism for the p.Glu314Lys variant, previously reported, and found in four additional patients with CYP11A1 deficiency. Subjects and Methods: DNA of four patients presenting with delayed PAI and/or 46,XY DSD were studied by Sanger or Massively Parallel sequencing. Three CYP11A1 mutations were characterized in vitro and in silico, and one by mRNA analysis on testicular tissue. Results: All patients were compound heterozygous for the previously described p.Glu314Lys variant. In silico studies predicted this mutation as benign with no effect on splicing but mRNA analysis found that it led to incomplete exon 5 skipping. This mechanism was confirmed by minigene experiment. The protein carrying this mutation without exon skipping should conserve almost normal activity, according to in vitro studies. Two other mutations found in trans, the p.Arg120Gln and p.Arg465Trp, had similar activity compared to negative control, consistent with the in silico studies. Conclusions: We provide biological proof that the p. Glu314Lys variant is pathogenic due to its impact on splicing and seems responsible for the moderate phenotype of the four patients reported herein. The present study highlights the importance of considering the potential effect of a missense variant on splicing when it is not predicted to be disease causing.
Collapse
Affiliation(s)
- Claire Goursaud
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- *Correspondence: Claire Goursaud
| | - Delphine Mallet
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Centre de Référence du Développement Génital: du Fœtus à l'Adulte, Filière Maladies Rares Endocriniennes, Bron, France
| | - Alexandre Janin
- Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Cardiogénétique Moléculaire, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Institut NeuroMyoGène, CNRS UMR 5310 – INSERM U1217, Université de Lyon 1, Lyon, France
| | - Rita Menassa
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Centre de Référence du Développement Génital: du Fœtus à l'Adulte, Filière Maladies Rares Endocriniennes, Bron, France
| | - Véronique Tardy-Guidollet
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Centre de Référence du Développement Génital: du Fœtus à l'Adulte, Filière Maladies Rares Endocriniennes, Bron, France
- Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Gianni Russo
- Centro di Endocrinologia dell'infanzia e dell'adolescenza, Ospedale San Raffaele, Milan, Italy
| | - Anne Lienhardt-Roussie
- Service de Pédiatrie Médicale, Hôpital de la mère et de l'enfant, CHU de Limoges, Limoges, France
| | | | - Ingrid Plotton
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Centre de Référence du Développement Génital: du Fœtus à l'Adulte, Filière Maladies Rares Endocriniennes, Bron, France
- Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Yves Morel
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Centre de Référence du Développement Génital: du Fœtus à l'Adulte, Filière Maladies Rares Endocriniennes, Bron, France
- Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Florence Roucher-Boulez
- Laboratoire de Biochimie et Biologie Moléculaire Grand Est, UM Pathologies Endocriniennes Rénales Musculaires et Mucoviscidose, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
- Centre de Référence du Développement Génital: du Fœtus à l'Adulte, Filière Maladies Rares Endocriniennes, Bron, France
- Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France
| |
Collapse
|
7
|
Blais R, Lienhardt-Roussie A, Fayemendy P, Desport J, Jésus P. OR48: Nonalcoholic Fatty Liver Disease in Children with Excess of Weight. Clin Nutr 2017. [DOI: 10.1016/s0261-5614(17)30739-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Abi Habib W, Brioude F, Edouard T, Bennett JT, Lienhardt-Roussie A, Tixier F, Salem J, Yuen T, Azzi S, Le Bouc Y, Harbison MD, Netchine I. Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction. Genet Med 2017; 20:250-258. [PMID: 28796236 PMCID: PMC5846811 DOI: 10.1038/gim.2017.105] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 05/29/2017] [Indexed: 12/26/2022] Open
Abstract
Purpose Fetal growth is a complex process involving maternal, placental and fetal factors. The etiology of fetal growth retardation remains unknown in many cases. The aim of this study is to identify novel human mutations and genes related to Silver–Russell syndrome (SRS), a syndromic form of fetal growth retardation, usually caused by epigenetic downregulation of the potent fetal growth factor IGF2. Methods Whole-exome sequencing was carried out on members of an SRS familial case. The candidate gene from the familial case and two other genes were screened by targeted high-throughput sequencing in a large cohort of suspected SRS patients. Functional experiments were then used to link these genes into a regulatory pathway. Results We report the first mutations of the PLAG1 gene in humans, as well as new mutations in HMGA2 and IGF2 in six sporadic and/or familial cases of SRS. We demonstrate that HMGA2 regulates IGF2 expression through PLAG1 and in a PLAG1-independent manner. Conclusion Genetic defects of the HMGA2–PLAG1–IGF2 pathway can lead to fetal and postnatal growth restriction, highlighting the role of this oncogenic pathway in the fine regulation of physiological fetal/postnatal growth. This work defines new genetic causes of SRS, important for genetic counseling.
Collapse
Affiliation(s)
- Walid Abi Habib
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France.,Service d'Explorations Fonctionnelles Endocriniennes, AP-HP, Hôpital Trousseau, Paris, France.,Current affiliation: Center for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA
| | - Frédéric Brioude
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France.,Service d'Explorations Fonctionnelles Endocriniennes, AP-HP, Hôpital Trousseau, Paris, France
| | - Thomas Edouard
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, University Hospital Center, Toulouse, France.,INSERM Unit 1043, Physiopathology Center of Toulouse Purpan (CTPT), Paul-Sabatier University, Toulouse, France
| | - James T Bennett
- Department of Pediatrics (Genetics), University of Washington, and Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA
| | - Anne Lienhardt-Roussie
- Département de Pédiatrie Médicale, Centre Hospitalo-Universitaire de Limoges, Limoges Cedex, France
| | - Frédérique Tixier
- Département d'Endocrinologie Pédiatrique, Hôpital Debrousse, Lyon, France
| | - Jennifer Salem
- RSS/SGA Research & Education Fund, MAGIC Foundation, Oak Park, Illinois, USA
| | - Tony Yuen
- Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Salah Azzi
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France.,Service d'Explorations Fonctionnelles Endocriniennes, AP-HP, Hôpital Trousseau, Paris, France
| | - Yves Le Bouc
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France.,Service d'Explorations Fonctionnelles Endocriniennes, AP-HP, Hôpital Trousseau, Paris, France
| | - Madeleine D Harbison
- Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Irène Netchine
- Sorbonne Universités, UPMC Univ Paris 06, UMR_S 938, CDR Saint-Antoine, Paris, France.,Service d'Explorations Fonctionnelles Endocriniennes, AP-HP, Hôpital Trousseau, Paris, France
| |
Collapse
|
9
|
Parween S, Roucher-Boulez F, Flück CE, Lienhardt-Roussie A, Mallet D, Morel Y, Pandey AV. P450 Oxidoreductase Deficiency: Loss of Activity Caused by Protein Instability From a Novel L374H Mutation. J Clin Endocrinol Metab 2016; 101:4789-4798. [PMID: 27603900 DOI: 10.1210/jc.2016-1928] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
CONTEXT P450 oxidoreductase (POR) is required for the activities of steroid-metabolizing cytochrome P450 enzymes in the endoplasmic reticulum. POR deficiency (PORD) is a form of congenital adrenal hyperplasia. Objective and Aim: Enzymatic and structural analysis of a novel L374H POR mutation from a patient with 46,XX disorder of sexual development. Design, Setting, Patient, and Intervention: The patient was a 46,XX girl with nonconsanguineous Turkish parents. She had virilized external genitalia at birth, a uterus and ovaries, and no sign of Antley-Bixler syndrome. The initial diagnosis was CYP21A2 deficiency with no mutations in CYP21A2, but POR mutations were found. Functional testing was done after producing recombinant POR proteins for analyzing enzymatic and structural properties. MAIN OUTCOME Novel mutations were causing severe loss of POR activities for metabolism of steroids and small molecules. RESULTS The L374H mutation reduced activities by 80% in cytochrome c, 97% in thiazolyl blue tetrazolium bromide, and 86% in ferricyanide reduction assays. The catalytic efficiency of the 17 α-hydroxylation of progesterone and the 17,20-lyase reaction of 17-OH pregnenolone was decreased by 87 and 90%, respectively; 21-hydroxylation of progesterone was decreased by 96%, and androstenedione aromatization was decreased by 90%. Analysis of the mutant structure by molecular dynamics simulations revealed structural instability. Flavin release and fast proteolysis assays showed that the L374H mutant is less stable than wild-type POR, confirming the bioinformatics prediction. CONCLUSIONS This is the first report of a mutation causing PORD by affecting protein stability that causes severe reduction in POR activities. Detailed characterization of individual mutations in POR is required for understanding novel molecular mechanisms causing PORD.
Collapse
Affiliation(s)
- Shaheena Parween
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| | - Florence Roucher-Boulez
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| | - Christa E Flück
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| | - Anne Lienhardt-Roussie
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| | - Delphine Mallet
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| | - Yves Morel
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| | - Amit V Pandey
- Pediatric Endocrinology, Diabetology, and Metabolism (S.P., C.E.F., A.V.P.), University Children's Hospital, and Department of Clinical Research, University of Bern, CH-3010 Bern, Switzerland; Service d'Endocrinologie Moléculaire et Maladies Rares (F.R.-B., D.M., Y.M.), Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, 69002 Bron-Lyon, France; and Endocrinologie Pédiatrique Département de Pédiatrie Médicale (A.L.-R.), Hôpital de la Mère et de l'Enfant, 87042 Limoges, France
| |
Collapse
|
10
|
Balazard F, Le Fur S, Valtat S, Valleron AJ, Bougnères P, Thevenieau D, Chatel CF, Desailloud R, Bony-Trifunovic H, Ducluzeau PH, Coutant R, Caudrelier S, Pambou A, Dubosclard E, Joubert F, Jan P, Marcoux E, Bertrand AM, Mignot B, Penformis A, Stuckens C, Piquemal R, Barat P, Rigalleau V, Stheneur C, Fournier S, Kerlan V, Metz C, Fargeot-Espaliat A, Reznic Y, Olivier F, Gueorguieva I, Monier A, Radet C, Gajdos V, Terral D, Vervel C, Bendifallah D, Signor CB, Dervaux D, Benmahammed A, Loeuille GA, Popelard F, Guillou A, Benhamou PY, Khoury J, Brossier JP, Bassil J, Clavel S, Le Luyer B, Bougnères P, Labay F, Guemas I, Weill J, Cappoen JP, Nadalon S, Lienhardt-Roussie A, Paoli A, Kerouedan C, Yollin E, Nicolino M, Simonin G, Cohen J, Atlan C, Tamboura A, Dubourg H, Pignol ML, Talon P, Jellimann S, Chaillous L, Baron S, Bortoluzzi MN, Baechler E, Salet R, Zelinsky-Gurung A, Dallavale F, Larger E, Laloi-Michelin M, Gautier JF, Guérin B, Oilleau L, Pantalone L, Lukas C, Guilhem I, De Kerdanet M, Wielickzo MC, Priou-Guesdon M, Richard O, Kurtz F, Laisney N, Ancelle D, Parlier G, Boniface C, Bockel DP, Dufillot D, Razafimahefa B, Gourdy P, Lecomte P, Pepin-Donat M, Combes-Moukhovsky ME, Zymmermann B, Raoulx M, Dumont AGEC. Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case-control study. BMC Public Health 2016; 16:1021. [PMID: 27682602 PMCID: PMC5041527 DOI: 10.1186/s12889-016-3690-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Accepted: 09/20/2016] [Indexed: 12/22/2022] Open
Abstract
Background The incidence of childhood type 1 diabetes (T1D) incidence is rising in many countries, supposedly because of changing environmental factors, which are yet largely unknown. The purpose of the study was to unravel environmental markers associated with T1D. Methods Cases were children with T1D from the French Isis-Diab cohort. Controls were schoolmates or friends of the patients. Parents were asked to fill a 845-item questionnaire investigating the child’s environment before diagnosis. The analysis took into account the matching between cases and controls. A second analysis used propensity score methods. Results We found a negative association of several lifestyle variables, gastroenteritis episodes, dental hygiene, hazelnut cocoa spread consumption, wasp and bee stings with T1D, consumption of vegetables from a farm and death of a pet by old age. Conclusions The found statistical association of new environmental markers with T1D calls for replication in other cohorts and investigation of new environmental areas. Trial registration Clinical-Trial.gov NCT02212522. Registered August 6, 2014. Electronic supplementary material The online version of this article (doi:10.1186/s12889-016-3690-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- F Balazard
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Paris, France. .,INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France.
| | - S Le Fur
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France.,Department of pediatric endocrinology, Hôpital Bicêtre, Kremlin-Bicêtre, France
| | - S Valtat
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France
| | - A J Valleron
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France
| | - P Bougnères
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France.,Department of pediatric endocrinology, Hôpital Bicêtre, Kremlin-Bicêtre, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Savas-Erdeve S, Sagsak E, Keskin M, Magdelaine C, Lienhardt-Roussie A, Kurnaz E, Cetinkaya S, Aycan Z. Treatment experience and long-term follow-up data in two severe neonatal hyperparathyroidism cases. J Pediatr Endocrinol Metab 2016; 29:1103-10. [PMID: 27390877 DOI: 10.1515/jpem-2015-0261] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 05/26/2016] [Indexed: 12/20/2022]
Abstract
The calcium sensing receptor (CASR) is expressed most abundantly in the parathyroid glands and the kidney. CASR regulates calcium homeostasis through its ability to modulate parathormone secretion and renal calcium reabsorption. Inactivating mutations in the CASR gene may result in disorders of calcium homeostasis manifesting as familial benign hypocalciuric hypercalcemia (FBHH) and neonatal severe hyperparathyroidsm (NSHPT). Two cases were referred with severe hypercalcemia in the neonatal period. Laboratory evaluation revealed severe hypercalcemia and elevated PTH. The parents also had mild hypercalcemia. The serum calcium level did not normalize with conventional hypercalcemia treatment and there was also no response to cinacalcet in case 1. Total parathyroidectomy was performed when the patient was 70 days old. Genetic analysis revealed a novel homozygous p.Arg544* mutation in the CASR gene. Case 2 underwent total parathyroidectomy and autoimplantation when she was 97 days old, but the parathyroid gland implanted into the forearm was removed 27 days later because the hypercalcemia continued. Genetic evaluation revealed a novel homozygous p.Pro682Leu mutation with normal anthropometric measurements. The neurological development is consistent with age in both cases while case 2 has mild mental retardation. No bone deformity or fracture is present in either case and normocalcemia is ensured with calcitriol in both cases.
Collapse
|
12
|
Voisin A, Lienhardt-Roussie A, Fayemendy P, Jésus P, Darthou-Pouchard L, Desport JC. Le syndrome d’hyperimmunoglobulinémie D peut être associé à une dénutrition ainsi qu’à des carences en phosphore et en vitamines. NUTR CLIN METAB 2015. [DOI: 10.1016/j.nupar.2015.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Champigny MA, Gaulier J, Lienhardt-Roussie A, Tahir A. P-146 – Criblage toxicologique aux urgences pédiatriques: état des lieux et perspectives de bonnes pratiques. Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30328-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Lambert A, Champigny M, Netchine I, Compain F, Bouvattier C, Lienhardt-Roussie A. CO-81 – Anomalies des organes génitaux externes anténatales: évaluation de l'annonce. Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30181-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Kahvecioglu D, Atasay B, Berberoglu M, Yildiz D, Cakir U, Akduman H, Erdeve O, Siklar Z, Magdelaine C, Lienhardt-Roussie A, Akar M, Ozbek MN, Arsan S. A novel mutation in the calcium sensing receptor gene in a neonate with severe hyperparathyroidism. Genet Couns 2014; 25:331-335. [PMID: 25365856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
16
|
Lia-Baldini AS, Magdelaine C, Nizou A, Airault C, Salles JP, Moulin P, Delemer B, Aitouares M, Funalot B, Sturtz F, Lienhardt-Roussie A. Two novel mutations of the calcium-sensing receptor gene affecting the same amino acid position lead to opposite phenotypes and reveal the importance of p.N802 on receptor activity. Eur J Endocrinol 2013; 168:K27-34. [PMID: 23169696 DOI: 10.1530/eje-12-0714] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
OBJECTIVE Gain-of-function mutations of the calcium-sensing receptor (CASR) gene have been identified in patients with sporadic or familial autosomal dominant hypocalcemia (ADH). Inactivating mutations of the CASR gene cause familial hypocalciuric hypercalcemia (FHH). Here, we report two novel CASR mutations affecting the same amino acid (p.N802); one causes ADH and the other atypical FHH. PATIENTS AND METHODS The first patient, an 11-year-old girl suffering from hypocalcemia, developed nephrocalcinosis when she was only 5 years old. The second patient is a 30-year-old woman who presented with mild hypercalcemia. PCR amplification of CASR coding exons and direct sequencing of PCR products were used to identify mutations. Site-directed mutagenesis was used to generate mutated CASR cDNAs in an expression plasmid. Using the MAPK assay system and transient transfection of Cos-7 cells with wild-type (WT) and mutated CASR, we studied the responses of these mutated receptors to extracellular Ca(2+) and to the negative allosteric CASR modulator, NPS2143. RESULTS Two heterozygous missense mutations (p.N802I and p.N802S) affecting a residue in the sixth transmembrane domain of CASR were identified. In functional tests, the response of the p.N802S mutant to calcium was typical of an inactivating mutation. However, the p.N802I mutant had 70% of the maximally stimulated WT receptor activity even in the absence of extracellular calcium. This constitutive activity was only partially inhibited by the inhibitor, NPS2143. CONCLUSIONS The asparagine at amino acid position 802 appears to be essential for the activity of the CASR protein and is implicated in the mechanism of CASR signaling.
Collapse
Affiliation(s)
- Anne-Sophie Lia-Baldini
- EA 6309 - Maintenance Myélinique et Neuropathies Périphériques, Faculté de Médecine - Biochimie, Université de Limoges, 6ème étage, 2 rue du Dr Marcland, 87025 Limoges, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Lienhardt-Roussie A. [Height and weight delay in growth]. Rev Prat 2011; 61:1133-1140. [PMID: 22135986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
18
|
Lienhardt-Roussie A. Hypercalcémie du nouveau-né en maternité. Arch Pediatr 2011. [DOI: 10.1016/s0929-693x(11)71071-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Tardy V, Menassa R, Sulmont V, Lienhardt-Roussie A, Lecointre C, Brauner R, David M, Morel Y. Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected in 46 patients affected with 21-hydroxylase deficiency and in one carrier. J Clin Endocrinol Metab 2010; 95:1288-300. [PMID: 20080860 DOI: 10.1210/jc.2009-1202] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Steroid 21-hydroxylase deficiency is the most common enzymatic defect causing congenital adrenal hyperplasia with genotype/phenotype relationships for common mutations. Novel mutations of the CYP21A2 gene must be well studied to propose right genetic counseling for patients. OBJECTIVE Thirteen CYP21 mutations have been studied. A detailed description of phenotype was performed for all mutations (p.I77T, p.L167P, p.I230T, p.R233K, p.G291S, p.G292D, p.E320K, p.R341P, p.R354H, p.R369W, p.R408C, p.G424S, and p.R426H). In vitro and in silico studies were performed only for those not previously described (p.L167P, p.I230T, p.R233K, p.G292D, p.E320K, and p.R369W). RESULTS Regarding phenotype, patients with 10 of these mutations had a classical form. A patient with isolated p.I230T presented with nonclassical form and a patient with the association p.I230T + p.V281L in cis presented with a more severe phenotype. The p.R233K mutation was detected in a carrier partner. A patient with p.R369W presented with an intermediate form. Functional studies showed that all mutations except p.I230T and p.R369W decreased enzyme activity more than p.P30L: severity of p.R369W was intermediate between p.P30L and p.V281L, and finally p.I230T was less severe than p.V281L. Mutation analysis in a three-dimensional model structure of the CYP21 protein explained the observed in vitro effects, severe mutations being implicated in important functional domains of the protein. CONCLUSION According to phenotype and functional studies, 11 of the mutations described, except the isolated p.R369W and p.I230T, may be responsible for a severe phenotype underlying the necessity to manage children having them. The p.I230T is a nonclassical mutation, and for the p.R369W, we need more cases to precise its severity.
Collapse
Affiliation(s)
- V Tardy
- Laboratoire d'Endocrinologie Moléculaire et Maladies Rares, Centre de Biologie et de Pathologie Est, 69677 Bron Cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Piñero A, Wolczynski S, Brailly-Tabard S, Bidet M, Ramos-Arroyo M, Mathieu M, Lienhardt-Roussie A, Morgan G, Turki Z, Bremont C, Lespinasse J, Du Boullay H, Chabbert-Buffet N, Jacquemont S, Reach G, De Talence N, Tonella P, Conrad B, Despert F, Delobel B, Brue T, Bouvattier C, Cabrol S, Pugeat M, Murat A, Bouchard P, Hardelin JP, Dodé C, Young J. A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab 2010; 95:659-69. [PMID: 20022991 DOI: 10.1210/jc.2009-0843] [Citation(s) in RCA: 100] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
CONTEXT Both biallelic and monoallelic mutations in PROK2 or PROKR2 have been found in Kallmann syndrome (KS). OBJECTIVE The objective of the study was to compare the phenotypes of KS patients harboring monoallelic and biallelic mutations in these genes. DESIGN AND PATIENTS We studied clinical and endocrine features that reflect the functioning of the pituitary-gonadal axis, and the nonreproductive phenotype, in 55 adult KS patients (42 men and 13 women), of whom 41 had monoallelic mutations and 14 biallelic mutations in PROK2 or PROKR2. RESULTS Biallelic mutations were associated with more frequent cryptorchidism (70% vs. 34%, P < 0.05) and microphallus (90% vs. 28%, P < 0.001) and lower mean testicular volume (1.2 +/- 0.4 vs. 4.5 +/- 6.0 ml; P < 0.01) in male patients. Likewise, the testosterone level as well as the basal FSH level and peak LH level under GnRH-stimulation were lower in males with biallelic mutations (0.2 +/- 0.1 vs. 0.7 +/- 0.8 ng/ml; P = 0.05, 0.3 +/- 0.1 vs. 1.8 +/- 3.0 IU/liter; P < 0.05, and 0.8 +/- 0.8 vs. 5.2 +/- 5.5 IU/liter; P < 0.05, respectively). Nonreproductive, nonolfactory anomalies were rare in both sexes and were never found in patients with biallelic mutations. The mean body mass index of the patients (23.9 +/- 4.2 kg/m(2) in males and 26.3 +/- 6.6 kg/m(2) in females) did not differ significantly from that of gender-, age-, and treatment-matched KS individuals who did not carry a mutation in PROK2 or PROKR2. Finally, circadian cortisol levels evaluated in five patients, including one with biallelic PROKR2 mutations, were normal in all cases. CONCLUSION Male patients carrying biallelic mutations in PROK2 or PROKR2 have a less variable and on average a more severe reproductive phenotype than patients carrying monoallelic mutations in these genes. Nonreproductive, nonolfactory clinical anomalies associated with KS seem to be restricted to patients with monoallelic mutations.
Collapse
Affiliation(s)
- Julie Sarfati
- Service d'Endocrinologie, Hôpital Bicêtre, 78 Rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ranger-Rogez S, Ribierre G, Ducroix-Roubertou S, Lienhardt-Roussie A, Vallat J, Denis F, Weinbreck P. O-05 Méningites et encéphalites à entérovirus diagnostiquées au CHU de Limoges : 2005-2006. Med Mal Infect 2008. [DOI: 10.1016/s0399-077x(08)73202-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Ponthier C, Marin B, Aubard Y, Lienhardt-Roussie A. SFP-23 – Diabétologie, endocrinologie – Allaitement maternel et surpoids dans la petite enfance : effet protecteur ? Arch Pediatr 2008. [DOI: 10.1016/s0929-693x(08)72090-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Dodé C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler ML, Lespinasse J, Lienhardt-Roussie A, Mathieu M, Moerman A, Morgan G, Murat A, Toublanc JE, Wolczynski S, Delpech M, Petit C, Young J, Hardelin JP. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006; 2:e175. [PMID: 17054399 PMCID: PMC1617130 DOI: 10.1371/journal.pgen.0020175] [Citation(s) in RCA: 297] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2006] [Accepted: 08/31/2006] [Indexed: 01/24/2023] Open
Abstract
Kallmann syndrome combines anosmia, related to defective olfactory bulb morphogenesis, and hypogonadism due to gonadotropin-releasing hormone deficiency. Loss-of-function mutations in KAL1 and FGFR1 underlie the X chromosome-linked form and an autosomal dominant form of the disease, respectively. Mutations in these genes, however, only account for approximately 20% of all Kallmann syndrome cases. In a cohort of 192 patients we took a candidate gene strategy and identified ten and four different point mutations in the genes encoding the G protein-coupled prokineticin receptor-2 (PROKR2) and one of its ligands, prokineticin-2 (PROK2), respectively. The mutations in PROK2 were detected in the heterozygous state, whereas PROKR2 mutations were found in the heterozygous, homozygous, or compound heterozygous state. In addition, one of the patients heterozygous for a PROKR2 mutation was also carrying a missense mutation in KAL1, thus indicating a possible digenic inheritance of the disease in this individual. These findings reveal that insufficient prokineticin-signaling through PROKR2 leads to abnormal development of the olfactory system and reproductive axis in man. They also shed new light on the complex genetic transmission of Kallmann syndrome.
Collapse
Affiliation(s)
- Catherine Dodé
- Institut Cochin, INSERM U567, Université René Descartes, Paris, France
- * To whom correspondence should be addressed. E-mail: (CD), (JPH)
| | - Luis Teixeira
- Institut Cochin, INSERM U567, Université René Descartes, Paris, France
| | - Jacqueline Levilliers
- Unité de Génétique des Déficits Sensoriels, INSERM U587, Institut Pasteur, Paris, France
| | - Corinne Fouveaut
- Laboratoire de Biochimie Génétique, Hôpital Cochin, Paris, France
| | | | | | - James Lespinasse
- Laboratoire de Génétique Chromosomique, Centre Hospitalier, Chambéry, France
| | | | - Michèle Mathieu
- Département de Pédiatrie, Centre Hospitalier, Amiens, France
| | | | | | - Arnaud Murat
- Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition, Hôtel-Dieu, Nantes, France
| | - Jean-Edmont Toublanc
- Service d'Endocrinologie Pédiatrique, Hôpital Saint-Vincent de Paul, Paris, France
| | - Slawomir Wolczynski
- Department of Reproduction and Gynecological Endocrinology, Bialystok, Poland
| | - Marc Delpech
- Institut Cochin, INSERM U567, Université René Descartes, Paris, France
| | - Christine Petit
- Unité de Génétique des Déficits Sensoriels, INSERM U587, Institut Pasteur, Paris, France
| | - Jacques Young
- Service d'Endocrinologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - Jean-Pierre Hardelin
- Unité de Génétique des Déficits Sensoriels, INSERM U587, Institut Pasteur, Paris, France
- * To whom correspondence should be addressed. E-mail: (CD), (JPH)
| |
Collapse
|
24
|
Lienhardt-Roussie A. [Contribution of genetic testing after diagnosis of hypocalcemia]. Ann Endocrinol (Paris) 2005; 66:207-15. [PMID: 15988381 DOI: 10.1016/s0003-4266(05)81752-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Serum calcium is a fine-tuned biological value. In recent years, fundamental research and study of molecular anomalies causing certain hereditary diseases of phosphocalcium metabolism have greatly contributed to our knowledge of the factors involved in this regulation, from the embryogenesis of the parathyroid glands to the assay value of serum calcium. Targeted research on these genetic anomalies would be useful not only for the clinician, but also for the patient, contributing to the etiological search, patient follow-up, and possibly to antenatal diagnosis. The main genetic anomalies identified to date are: CaSR, GNAS, AIRE, VDR, mitochondrial DNA, 22q11 deletion.
Collapse
|
25
|
Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, Ristaldi MS, Marzella R, Rocchi M, Nicolino M, Lienhardt-Roussie A, Nivelon A, Verloes A, Schlessinger D, Gasparini P, Bonneau D, Cao A, Pilia G. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27:159-66. [PMID: 11175783 DOI: 10.1038/84781] [Citation(s) in RCA: 625] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In type I blepharophimosis/ptosis/epicanthus inversus syndrome (BPES), eyelid abnormalities are associated with ovarian failure. Type II BPES shows only the eyelid defects, but both types map to chromosome 3q23. We have positionally cloned a novel, putative winged helix/forkhead transcription factor gene, FOXL2, that is mutated to produce truncated proteins in type I families and larger proteins in type II. Consistent with an involvement in those tissues, FOXL2 is selectively expressed in the mesenchyme of developing mouse eyelids and in adult ovarian follicles; in adult humans, it appears predominantly in the ovary. FOXL2 represents a candidate gene for the polled/intersex syndrome XX sex-reversal goat.
Collapse
Affiliation(s)
- L Crisponi
- Istituto di Ricerca sulle Talassemie ed Anemie Mediterranee CNR, and Dipartimento di Scienze Biomediche e Biotecnologie, Ospedale Regionale per le Microcitemie, Università degli Studi di Cagliari, Cagliari, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|